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Background. In type 1 diabetic patients with end-stage renal
failure, low bone mass is prevalent and the incidence of fractures
high after simultaneous pancreas kidney transplantation (SPK).
Data are scarce on preexisting skeletal morbidity or the long-
term effects of SPK on bone mass and risk of fractures.
Methods. We conducted a prospective study addressing these
issues in 19 consecutive SPK recipients before and at 3, 6,
and 12 months, and 2.5 to 4 years after establishment of graft
function.
Results. Prior to transplantation, 13 patients (68%) had hy-
perparathyroidism, 7 of whom had osteoporosis. Mean bone
mineral density (BMD) was significantly lower at the femoral
neck than at the lumbar spine (T-scores −2.0 ± 0.89 vs. −0.66 ±
0.84). There was a significant decrease in BMD at both lum-
bar spine and femoral neck at 6 months post-transplantation
(−6.0 ± 5.4% and −6.9 ± 4.3%, respectively). No further
loss was observed in the following 6 months. At 1 year post-
transplantation, 9 patients had osteoporosis associated with
hyperparathyroidism in 8, and none had sustained a clinical
fracture. A significant albeit small increase in BMD was ob-
served 6 months after start of alfacalcidol 0.25 lg/day. At end-
evaluation, osteoporosis and hyperparathyroidism persisted in
the patients in whom it was documented at 1 year. Five patients
who had lower BMD at the femoral neck pretransplantation
sustained a clinical fracture.
Conclusion. Cortical osteoporosis is prevalent in SPK re-
cipients at the time of transplantation, progresses early post-
transplantation, and is associated with relatively high incidence
of fractures. Reversal of persistent hyperparathyroidism with
the use of alfacalcidol may contribute to a decrease in skeletal
morbidity.
Simultaneous pancreas-kidney (SPK) transplantation
is currently established as the treatment of choice for pa-
tients with type 1 diabetes mellitus and end-stage dia-
betic nephropathy, successfully restoring normoglycemia
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and providing adequate renal function [1, 2]. Technical
success rates have improved over the last decade, re-
sulting in prolonged graft survival, thereby also increas-
ing potential morbidity from other complications of the
transplant process. There had recently been increased in-
terest in addressing long-term morbidity aiming at re-
ducing it in SPK transplant recipients. In keeping with
other organ transplantation, bone loss and consequent
increase in fracture rate is prevalent after SPK trans-
plantation because of the compulsory immunosuppres-
sive regimen, including glucocorticoids [3, 4]. We have
indeed shown in a cross-sectional study, conducted more
than one year after SPK, that osteoporosis is prevalent
after successful transplantation, and that it is associated
with a high incidence of mainly nonvertebral fractures in
up to 45% of patients [5]. Intriguingly, and contrary to ex-
pectation if solely due to use of high dose glucocorticoids,
osteoporosis was predominant at cortical sites. The risk
of fracture is apparently also greater in SPK transplant
recipients compared with kidney transplant recipients
[4, 6].
In most solid organ transplant recipients, the use of glu-
cocorticoids is thought to be the main cause of bone loss
[7]. In simultaneous pancreas-kidney transplant recipi-
ents, however, other factors may well play a more promi-
nent role. First, preexisting type 1 diabetes mellitus has
been shown to be associated with low turnover bone dis-
ease and osteopenia [8–10]. Second, diabetic nephropa-
thy and subsequent progressive renal failure is likely to be
associated with secondary hyperparathyroidism, which
also leads to bone loss [11–13].
In SPK recipients, data are scarce on preexisting skele-
tal pathology, and on the time course and characteriza-
tion of bone loss following transplantation, particularly
in the long-term. The aim of our study was 2-fold: first,
to characterize skeletal morbidity before transplantation,
and second, to determine changes occurring in the years
following establishment of graft function. Pathophysio-
logic processes involved are discussed, and clinical impli-
cations of our findings are outlined.
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METHODS
Patients
We studied 22 consecutive patients with type 1 dia-
betes mellitus and end-stage renal failure who underwent
simultaneous pancreas-kidney transplantation at the Lei-
den University Medical Center between 1995 and 1997.
Three patients were excluded from the study, 2 because
they had parathyroidectomy before transplantation, and
1 because of a nonfunctioning kidney graft and return to
dialysis. Failure of the pancreas graft was not an exclusion
criterion.
Study design
This was a prospective study in which patients were
evaluated before the transplantation, as part of the pre-
transplant work-up, and at regular intervals thereafter
for 18 months post-transplant (3, 6, 12, and 18 months).
A further single end-evaluation was undertaken 21/2 to
4 years after transplantation. Each evaluation consisted
of a full clinical examination, laboratory investigations,
and bone mineral density (BMD) measurements. All clin-
ical fractures were carefully documented and confirmed
radiologically.
At the end of the first year post-transplantation, all
patients were started on the synthetic analog of active
vitamin D (alfacalcidol) at a fixed dose of 0.25 lg per day.
Informed consent was obtained from all patients.
Transplantation procedure
Simultaneous pancreas-kidney transplantation was
performed using the bladder-drainage technique with sys-
temic insulin delivery. All calcium/vitamin D/phosphate-
binders were stopped at the time of transplantation. All
patients received triple immunosuppressive therapy in-
cluding glucocorticoids, microemulsion cyclosporine, and
mycophenolate mofetil (2 g/day) or azathioprine (1.5–
2.0 mg/kg/day; N = 7). Prednisone was started at a dose
of 50 mg twice daily for the first 3 days, quickly tapered
to 20 mg daily at 4 weeks, 15 mg daily at 3 months, and
10 mg daily from 9 months onwards. Cyclosporine was
started at a dose of 8 to 10 mg/kg/day, aiming for trough
serum levels of 300 ng/mL (range 250–350 ng/mL). The
dosage was adjusted from 3 months post-transplant on-
ward, to maintain a trough level of 150 ng/mL (range 100–
200 ng/mL). No prophylactic therapy with poly- or mon-
oclonal antibodies was given. Rejection episodes were
treated with 3 1-g pulses of methylprednisolone (Solu-
Medrol; Pharmacia, Woerden, The Netherlands), and
steroid-resistant episodes with anti-thymocyte globulin
(ATG; RIVM, Bilthoven, The Netherlands). In the event
of a third rejection episode, treatment with methylpred-
nisolone was repeated, sometimes followed by OKT3
rescue therapy, depending on the patients’ clinical con-
dition. Immunosuppression was altered to cyclosporine
and prednisone only in the event of loss of pancreatic graft
function. All patients received individually tailored doses
of bicarbonate to correct for their tendency to metabolic
acidosis.
Laboratory investigations
Graft function was determined at each time point by
measuring endogenous creatinine clearance and HbA1c
concentrations. Serum calcium, albumin, creatinine, and
alkaline phosphatase activity, and urine calcium and cre-
atinine were measured by automated techniques. Serum
calcium concentrations were adjusted to an albumin
concentration of 42 g/L. Plasma parathyroid hormone
(PTH) concentrations were measured by an immunora-
diometric assay, detecting the intact molecule (Nichols
Institute Diagnostics, Wijchen, The Netherlands), and
serum 25-hydroxy vitamin D (25-OHD) and 1,25-
hydroxyvitamin D (1,25-(OH)2-D), and osteocalcin by
commercial radioimmunoassays (Incstar/DiaSorin, Still-
water, MN, USA).
Bone densitometry
Bone mineral density measurements (BMD) were un-
dertaken at the lumbar spine (L1-L4) and at the femoral
neck using dual x-ray absorptiometry (Hologic QDR
1000 or Hologic QDR 4500; Hologic, Waltham, MA,
USA). At some stage during follow-up our nuclear
medicine department switched to measuring BMD ex-
clusively using the Hologic QDR 4500 densitometer. A
conversion formula obtained from double bone densit-
ometry measurements on 300 patients on both the Ho-
logic QDR 1000 and the Hologic QDR 4500 allowed us
to follow-up changes in bone mineral density across this
period (it must be noted that the conversion formula had
to be applied in 3 patients only). The formula we used
was:
At the lumbarspine : BMDHologicQDR1000
= (BMDHologicQDR4500 − 0.0109)/0.9736
At the femoral neck : BMDHologicQDR1000
= (BMDHologicQDR4500 − 0.01195)/0.98025
Changes in BMD (delta) were calculated using the ab-
solute values for BMD (g/cm2). Further results are ex-
pressed as T- and Z-scores, respectively, denoting the
number of standard deviations below the mean for young
adults and age- and sex-matched controls. WHO criteria
were used to define osteoporosis (T-score <−2.5) and
osteopenia (T-score >−2.5, <−1) [14].
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Table 1. Patients’ characteristics at the time of simultaneous
pancreas-kidney transplantation (N = 19)
Mean ± SD/N %
Gender
Male 13 68
Female 6 32
Age years 39 ± 7.4
Body mass index kg/m2 23 ± 2.5
Duration of diabetes years 25 ± 5.6
HbA1c % 8.6 ± 1.4
Renal replacement therapy
None 9 47
Hemodialysis 4 21
Peritoneal dialysis 6 32
Duration of dialysis monthsa 17 ± 12
aOnly patients with dialysis were included.
Statistical analysis
Values are expressed as mean ± standard deviation
except where otherwise indicated. Non-normally dis-
tributed variables such as PTH and osteocalcin were
log- transformed before analysis. The SPSS for Windows
software package (Chicago, IL, USA) was used for all
statistical analysis. Fisher exact tests were used to com-
pare nominal variables, and independent samples Stu-
dent t tests for continuous variables. Paired Student t tests
were applied to compare continuous variables before and
after transplantation. Pearson’s correlation’s coefficient
was used as necessary. A P value of < 0.05 was considered
statistically significant.
RESULTS
Baseline evaluation
Patients. There were 13 (68%) men and 6 (32%)
women with a mean age of 39 ± 7.4 years. Five of the
6 female patients were premenopausal, 3 of whom were
on oral contraceptives. The 1 postmenopausal female pa-
tient was not treated with hormone replacement therapy.
None of the male patients had hypogonadism. Ten pa-
tients (53%) were on dialysis. Mean creatinine clearance
of the other 9 patients was 18 ± 7 mL/min. Pretrans-
plant baseline patients’ characteristics are summarized in
Table 1. Baseline evaluation was performed within 1 year
prior to transplantation in all patients (mean 6.3 ± 2.8
months).
Laboratory investigations. Three patients had mildly
elevated serum calcium concentrations, with adequately
suppressed PTH values in 2, and a raised PTH in the third,
indicating parathyroid autonomy. Serum phosphate con-
centration was increased in 14 patients. Serum osteocalcin
concentrations were increased in 15 of the 16 patients in
whom this parameter of bone formation was measured. A
total of 13 patients (68%) had evidence for secondary hy-
perparathyroidism as defined before transplantation by
PTH levels >10 pmol/L in the presence of low or normal
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Fig. 1. Bone mineral density in T-scores (mean ± SD; solid bars) and
Z-scores (mean ± SD; hatched bars) at the lumbar spine (left) and
the femoral neck (right) at baseline evaluation before simultaneous
pancreas kidney transplantation.
serum calcium concentrations. 25-OH vitamin D mea-
surements were decreased in 4 patients, who also all had
elevated PTH levels. There was a significant relationship
between PTH and osteocalcin concentrations (r = 0.60,
P = 0.014).
Bone mineral density. Seven patients (37%) had corti-
cal osteoporosis as evidenced by a femoral neck T-score
below – 2.5 SD before transplantation (mean T-score
−2.0 ± 0.89 SD; mean Z-score −1.34 ± 0.91; Fig. 1). In
contrast, none of the patients had osteoporosis at the lum-
bar spine prior to transplantation (mean T-score −0.66 ±
0.84 SD; mean Z-score −0.41 ± 0.93). Patients on dialy-
sis before transplantation had significantly lower femoral
neck T- and Z-scores than patients who did not dialyze
(T-score −1.4 ± 0.8 vs. –2.6 ± 0.5; Z-score −0.7 ± 0.8 vs.
−1.9 ± 0.6; both P = 0.001), but there was no difference
in lumbar spine T- and Z-scores. There was no correlation
of log-transformed PTH and osteocalcin concentrations
with BMD measurements.
Accurate fracture data were not available pretrans-
plantation.
Sequential changes within the first year
post-transplantation
As per inclusion criteria, all 19 patients had sufficient
kidney function throughout the first year after trans-
plantation, with endogenous creatinine clearance rang-
ing from 28 to 115 mL/min. Seventeen patients (89%)
were normoglycemic and insulin-independent, indicat-
ing adequate function of the pancreatic graft. None of
the patients received hormone replacement therapy af-
ter transplantation. Sixteen patients (84%) had a mean of
2 rejection episodes (range 1 to 4). All rejection episodes
took place within the first 6 months post-transplantation.
The effect of cumulative prednisone doses on various out-
come variables could not be adequately assessed because
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Table 2. Biochemical parameters of bone and mineral metabolism in serum (mean ± SD)
Prior to SPK 3 months 6 months 12 months 18 months 30–48 months
N = 19 N = 18 N = 19 N = 19 N = 12 N = 17 Normal values
Creatinine mmol/L 649 ± 277 148 ± 36 144 ± 38 139 ± 42 143 ± 31 150 ± 61 70–133
Calcium mmol/La 2.38 ± 0.21 2.38 ± 0.12 2.36 ± 0.1 2.33 ± 0.1 2.29 ± 0.1 2.41 ± 0.1 2.25–2.55
Phosphate mmol/L 1.74 ± 0.47 0.9 ± 0.2 1.0 ± 0.1 1.1 ± 0.2 1.1 ± 0.2 NA 0.81–1.45
Alkaline phosphatase U/L 97 ± 39 101 ± 39 106 ± 34 98 ± 26 89 ± 32 77 ± 25 40–120
Osteocalcin lg/L 12.1 ± 6.6 3.7 ± 2.7 5.2 ± 3.2 5.8 ± 3.3 4.8 ± 2.7 NA <5.5
25-OHD nmol/Lb 49 ± 23 30 ± 17 35 ± 14 30 ± 16 51 ± 17 NA 30–120
1,25-(OH)2-D pmol/Lc 30 ± 17 43 ± 21 58 ± 24 61 ± 28 55 ± 18 NA 40–140
Parathyroid hormone pmol/L 17 ± 13 11 ± 11 6.6 ± 3.5 10.9 ± 13 6.7 ± 7.0 10.0 ± 6.7 <6.5
NA, not available.
aCalcium corrected for an albumin of 42 g/L.
b25-OHD: 25-hydroxyvitamin D.
c1,25-(OH)2-D: 1,25-hydroxyvitamin D.
the cumulative prednisone dosage was similar in the ma-
jority of the patients.
Laboratory investigations. Serum calcium concentra-
tions were within the normal laboratory reference range
in all but 2 patients, who had mildly elevated concen-
trations throughout the study. Serum phosphate concen-
trations normalized in due course in all patients, with 5
patients having mild transient hypophosphatemia early
post-transplantation. Serum osteocalcin concentrations
decreased in all patients during the first 3 months post-
transplantation (P < 0.001), and this decrease was sus-
tained throughout the year. In contrast, alkaline phos-
phatase activity was within the normal range and did
not change throughout the year. Mean PTH levels sig-
nificantly decreased post-transplantation (P = 0.001 at
6 months), although 8 patients (42%) still demonstrated
evidence for hyperparathyroidism at the 1-year time
point. There was a significant correlation between serum
PTH and osteocalcin concentrations (r = 0.79; P < 0.001).
Sequential changes in biochemical parameters of bone
and mineral metabolism are summarized in Table 2.
Bone mineral density. There was a rapid decrease in
mean BMD at both lumbar spine and femoral neck sites
observed as early as 3 months, persisting at 6 months post-
transplantation. No further bone loss was observed at
either site from 6 months onward. Changes in BMD mea-
surements after transplantation are illustrated in Figure
2. All but 1 patient experienced bone loss at the lum-
bar spine site within 3 months after transplantation, with
a maximum loss of 10% (mean change −5.1 ± 3.3%;
P < 0.001). Mean bone loss at the femoral neck was 3.7 ±
3.8% at the 3-month evaluation (P = 0.001). In the major-
ity of patients (63%) the lumbar spine BMD decreased
further between 3 and 6 months post-transplantation to
94 ± 4.3% of baseline. Similarly, all patients showed a
decrease in BMD at the femoral neck during the first
6 months after transplantation (mean loss 6.9 ± 5.4%;
P < 0.001). Mean BMD remained stable at both the lum-
bar spine and the femoral neck between 6 months and 1
year after transplantation (mean change 0.0 ± 3.0%, P =
NS, and −1.0 ± 4.2%, respectively, P = NS). Compared
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Fig. 2. Mean ± SD percent changes in bone mineral density at the
lumbar spine (open circles) and the femoral neck (closed triangles) in
SPK transplant recipients. Baseline evaluation is presented at the 0-
month time point.
to baseline evaluation, 9 patients had osteoporosis at the
femoral neck (47%), and only 1 patient (5%) at the lum-
bar spine at 1 year post-transplantation. There was no
correlation between initial BMD and the amount or rate
of bone loss.
None of the patients experienced clinical fractures dur-
ing the first year after transplantation.
Long-term follow-up
Seventeen patients were evaluated 21/2 to 4 years after
transplantation (mean 40±6 months). One patient devel-
oped bronchus carcinoma and widespread skeletal metas-
tases and died 3 years after transplantation. The other
chose to discontinue his participation in the study for
personal reasons. Twelve patients had an additional
evaluation at 18 months post-transplantation. Kidney
graft function remained stable in all patients during
follow-up (endogenous creatinine clearance range 29 to
99 mL/min). Two patients lost their pancreas graft func-
tion 1 and 3 years post-transplant, and had to return to
2074 Smets et al: Bone mineral density and SPK transplantation
insulin injections. HbA1c measurements were in the nor-
mal range in 16 patients (84%). The 3 patients on insulin
had HbA1c levels of 7.8% to 11.5%. From 1 year onward,
all patients received alfacalcidol at a fixed dose of 0.25 lg
per day.
Laboratory investigations. There was a significant in-
crease in serum calcium concentration (+ 0.08 ± 0.02
mmol/L; P = 0.002) in the first 6 months following the
start of treatment with alfacalcidol. This was not as-
sociated with a significant decrease in PTH. At end-
evaluation, 10 patients (59%) had persistently elevated
PTH levels.
Bone mineral density. A significant increase in BMD
was observed at the lumbar spine in the first 6 months
following start of alfacalcidol treatment (mean + 1.7 ±
2.1%; N = 11; P = 0.028). BMD at the femoral neck also
increased, albeit nonsignificantly.
At end-evaluation, overall mean BMD loss compared
with baseline was 4.6 ± 5.7% at the lumbar spine, and
4.6 ± 4.7% at the femoral neck (P = 0.006 and P =
0.001, respectively). As a result of this, mean T-score at
the lumbar spine was –1.0 ± 1.0 SD, and mean T-score
at the femoral neck –2.3 ± 1.0 SD at end-evaluation.
Mean Z-scores were −0.7 ± 1.2 SD at the lumbar spine,
and −1.5 ± 1.1 SD at the femoral neck. Compared with
baseline, 9 patients (47%) had osteoporosis at the
predominantly cortical femoral neck site. Only 1 pa-
tient developed osteoporosis at the lumbar spine
(5%). There were no differences in BMD observed
between patients with or without pancreas graft
function.
Fractures. Five patients (29%) sustained clinical frac-
tures more than 1 year after transplantation (range 1.3–
4.0 years). Most fractures occurred at peripheral sites
(feet). Two patients had multiple peripheral fractures
(clavicle/foot and humerus/foot). One patient had both
a vertebral and a peripheral fracture (radius). Patients
with fractures had a higher mean serum osteocalcin con-
centration at the pretransplant work-up (18.8 ± 7.1 lg/L
vs. 9.1 ± 3.7 lg/L; P = 0.003). Patients with fractures
also had significantly lower T-scores at the femoral neck
site before transplantation (−2.6 ± 0.7 SD vs. –1.7 ± 0.9
SD; P = 0.033). These significantly lower T-scores per-
sisted throughout the first year post-transplant. Patients
who sustained fractures had significantly higher PTH
and osteocalcin concentrations, and significantly lower
T-scores at the femoral neck 1 year post-transplantation
than their counterparts without fractures, although they
did not demonstrate more accelerated bone loss. There
were no differences in sex, age, rejection episodes, im-
munosuppressive regimens, or post-transplantation kid-
ney and pancreas function between patients with or
without fractures. Table 3 summarizes pre- and post-
transplant factors in patients with and without fractures
post-transplantation.
Table 3. Characteristics of patients with and without fractures after
transplantation
No fracture Fracture
(N = 13) (N = 6)
Pretransplant factors
Patients on dialysis % 4 (31%)a 6 (100%)a
Parathyroid hormone pmol/L 15.2 ± 12 20.4 ± 15
Osteocalcin lg/L 9.1 ± 3.7a 18.8 ± 7.1a
HbA1c % 8.9 ± 1.9 8.3 ± 1.1
BMD at femoral neck (T-score; SD) −1.7 ± 0.9a −2.6 ± 0.7a
BMD at lumbar spine (T-score; SD) −0.5 ± 0.8 −1.0 ± 1.0
Posttransplant factors (12 months)
Creatinine clearance mL/min 65 ± 19 60 ± 27
Parathyroid hormone pmol/L 5.6 ± 2.7a 20.7 ± 19a
Osteocalcin lg/L 4.3 ± 1.7a 8.3 ± 3.9a
HbA1c % 6.1 ± 1.8 5.7 ± 0.5
BMD at femoral neck (T-score; SD) −2.0 ± 0.9a −3.0 ± 0.7a
BMD at lumbar spine (T-score; SD) −1.2 ± 0.9 −1.5 ± 1.2
BMD loss at femoral neck % 5.4 ± 3.4 6.1 ± 5.9
BMD loss at lumbar spine % 6.0 ± 5.9 5.8 ± 5.9
Except when otherwise indicated, all results are expressed as mean ± SD.
aP < 0.05.
DISCUSSION
To our knowledge, this is the first study reporting se-
quential changes in bone mineral density and risk of
fracture in simultaneous pancreas-kidney transplant re-
cipients from before transplantation up to 4 years after
successful establishment of graft function. We have pre-
viously reported a high incidence of cortical osteoporosis
and peripheral fractures in SPK transplant recipients in
a cross-sectional study undertaken more than 1 year af-
ter transplantation [5]. Our data from the present study
establish preexisting cortical osteoporosis at the time of
transplantation, likely to be related to the diabetic state,
as the major cause for the high skeletal morbidity in SPK
transplant recipients although secondary hyperparathy-
roidism due to renal impairment also plays a contribu-
tory role. We also confirm the significant bone loss ob-
served overall in solid organ transplant recipients, within
the first 6 months post-transplantation. This loss is likely
to be due to glucocorticoid use as part of the immuno-
suppressive regimen. However, contrary to expectation,
we show no further bone loss past the first 6 months
post-transplantation, and a significant, albeit marginal,
increase in BMD following treatment with alfacalcidol.
Of note is that, despite the early decrease in BMD pa-
tients sustained clinical fractures only a year after trans-
plantation. The fact that the vast majority were peripheral
fractures is not surprising considering the predominantly
cortical osteoporosis.
Patients with type 1 diabetes mellitus have been shown
to have a low bone mass, particularly at cortical sites [15–
19]. In diabetic patients, low bone formation rates are be-
lieved to account for the low bone turnover state [8–10].
The development of diabetic nephropathy and progres-
sive renal failure adds another dimension to the bone
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pathology. Secondary hyperparathyroidism is common
in patients with end-stage renal failure, and is associ-
ated with high bone turnover and a decrease in predomi-
nantly cortical bone mineral density [11–13]. In our study,
secondary hyperparathyroidism was prevalent, and high
bone turnover was suspected by the increased osteocal-
cin levels in the majority of patients. These findings some-
what contrast with the commonly described low turnover
state characterizing patients with type 1 diabetes mellitus
[8, 9]. Rix et al observed that bone mineral density de-
creased parallel to declining renal function, and that the
decrease was most pronounced in the femoral neck. The
combination of type 1 diabetes mellitus and impaired re-
nal function was associated with lower bone mineral den-
sity measurements than those observed in patients with
renal failure not due to diabetes [13]. As expected with
the high prevalence of cortical osteoporosis, an increase
in the risk of hip fracture was recently documented in a
large registry study of patients with end-stage renal fail-
ure [20].
Post-transplantation bone disease has been well
documented after solid organ transplantation [3]. Im-
munosuppressive agents together with persistent hyper-
parathyroidism are believed to be the main cause of bone
loss in renal transplant recipients. It has clearly been
shown that the use of high-dose glucocorticoids leads
to rapid bone loss during the first months after trans-
plantation, mainly affecting trabecular bone [21–23]. The
effect of cyclosporine, azathioprine, and mycophenolate
mofetil appears to be limited [3, 24]. In the present study,
we demonstrate a pattern of accelerated trabecular and
cortical bone loss during the first 6 months after simul-
taneous pancreas-kidney transplantation. These findings
are consistent with those found in kidney transplant re-
cipients in the early stages after transplantation, and are
highly likely to be related to the high levels of immuno-
suppression required early after transplantation [23, 25,
26]. Our data on stabilization of bone mineral density af-
ter the first 6 months post-transplantation are in contrast
with those of Julian et al, who observed a continuing de-
crease in bone mineral density up to 18 months in kidney
transplant recipients [23]. Other studies have also demon-
strated slow ongoing bone loss [27, 28], while Grotz et al
found that the bone loss was limited to the first year in
kidney transplant recipients [26].
Our patients were uniformly treated with a fixed dose
of alfacalcidol of 0.25 lg per day from a year after trans-
plantation onward. We observe a significant albeit small
increase in bone mineral density in those patients in
whom it was measured within 6 months of starting treat-
ment (N = 11). We may have been too cautious in the
design of our study by restricting the dose of alfacal-
cidol to 0.25 lg per day. The persistence of secondary
hyperparathyroidism despite treatment with alfacalcidol
indeed suggests that this dose may have been insufficient
to normalize PTH secretion. Even so, the role of alfa-
calcidol in maintaining bone mineral density is difficult
to accurately assess, as numbers are small, duration of
evaluation short, and we have not studied a comparable
group of patients not receiving this agent.
A marked increase in the incidence of fractures is re-
ported after solid organ transplantation, particularly in
kidney transplant recipients with diabetes [4, 29, 30].
Pancreas-kidney transplant recipients are at increased
risk of fracture compared with recipients of kidney trans-
plants alone, with a recorded fracture prevalence of
nearly 50% [6]. In a previously published cross-sectional
study, we found a comparable, predominantly nonverte-
bral fracture rate of 45% more than 1 year after simulta-
neous pancreas-kidney transplantation [5]. In the present
study, clinical fractures were sustained in about a third of
patients over a mean follow-up period of 3.3 ± 0.5 years.
Patients who have sustained a fracture indeed had a low
bone mass predominantly at the cortical femoral neck
site at the pretransplant work-up. The lower fracture rate
we observe is possibly due to an underestimate of addi-
tional silent fractures, as only symptomatic clinical frac-
tures were recorded.
All fractures were sustained more than 1 year after
transplantation. The late timing of the fractures has sig-
nificant implications for the clinical management of these
patients, as more time may be available to implement
preventive measures. The use of lowest possible dose
of prednisone and adequate supplementation with cal-
cium and vitamin D has been advocated as prevention for
osteoporosis after organ transplantation [7, 22, 31]. Sup-
plementation with both calcium and vitamin D is also rec-
ommended in glucocorticoid-induced osteoporosis [32,
33]. A recent study in kidney transplant recipients showed
that treatment with low dose vitamin D and calcium par-
tially prevents the initial rapid bone loss observed in the
first 6 months after transplantation [34]. A beneficial ef-
fect of this therapeutic maneuver was observed at both
lumbar spine and femoral neck sites. In our patients, al-
facalcidol treatment appeared to result in a significant
increase in lumbar spine bone density, but these find-
ings should be interpreted with caution because of limited
numbers and lack of a control group. Although bisphos-
phonates have been shown to be effective in preventing
bone loss and increasing bone mass in glucocorticoid-
induced osteoporosis [32], data on the use in solid
organ transplantation are scarce [7, 35, 36]. Whether
bisphosphonates would be beneficial in decreasing the
risk of fracture in SPK transplant recipients remains to
be explored.
CONCLUSION
We observe that skeletal morbidity is high in pa-
tients undergoing simultaneous pancreas-kidney trans-
plantation. Cortical osteoporosis is prevalent due to the
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preexisting diabetic state and secondary hyperparathy-
roidism, which persists after transplantation. Significant
bone loss is observed within 6 months of transplan-
tation at both trabecular and cortical sites, and the
risk of fractures is significantly increased after the first
year of transplantation. Our data hold important clinical
implications in the management of SPK transplant recip-
ients. The significant contributory role of secondary hy-
perparathyroidism in the pathophysiology of bone loss
before and after transplantation suggests that adequate
therapeutic interventions, mainly using active metabo-
lites of vitamin D, should be implemented long before
SPK transplantation is considered, and certainly contin-
ued thereafter. Whether additional treatment with bis-
phosphonates could further decrease skeletal morbidity
remains to be established.
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